Study

“The Buzz” Show: Evaxion Biotech (NASDAQ: EVAX) Reaches Milestone in EVX-01 Development

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Evaxion Biotech Reaches Milestone in EVX-01 Development” Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, reached an important milestone announcing today that it had enrolled its first patient in the global phase …

“The Buzz” Show: Evaxion Biotech (NASDAQ: EVAX) Reaches Milestone in EVX-01 Development Read More »

“The Buzz” Show: Addex Pharmaceuticals (NASDAQ: ADXN) Terminates Dipraglurant Phase 2b/3 Study

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Addex Pharmaceuticals Terminates Dipraglurant Phase 2b/3 Study” Addex Therapeutics Ltd (NASDAQ: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson’s …

“The Buzz” Show: Addex Pharmaceuticals (NASDAQ: ADXN) Terminates Dipraglurant Phase 2b/3 Study Read More »

“The Buzz” Show: Radius Health, Inc. (NASDAQ: RDUS) & Menarini Group Announce EMERALD Study Results

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Radius Health, Inc. and Menarini Group Announce Positive Phase 3 Topline Results from the EMERALD Study” Radius Health, Inc. (NASDAQ: RDUS) surged over 37% in premarket trading after the company and the Menarini Group announced positive topline results from the EMERALD study. The study …

“The Buzz” Show: Radius Health, Inc. (NASDAQ: RDUS) & Menarini Group Announce EMERALD Study Results Read More »